NATIONAL CHENG KUNG UNIVERSITY, TAINAN, TAIWAN
BANYAN
Volume 26 Issue 8 - June 6, 2014
Add Bookmark RSS Subscribe BANYAN
Commentary
Article Digest
Dong-Hwang Chen
Vancomycin-modified LaB6@SiO2/Fe3O4 composite nanoparticles for near-infrared photothermal ablation of bacteria
Han-Ching Wang
Spawning stress triggers WSSV replication in brooders via the activation of shrimp STAT
Kung-Chia Young
Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III
Ming-Yang Cheng
Development of a Recurrent Fuzzy CMAC with Adjustable Input Space Quantization and Self-Tuning Learning Rate for Control of a Dual-Axis Piezoelectric Actuated Micro Motion Stage
News Release
NCKU Press Center
NCKU hosts international symposium on public diplomacy and regional business
NCKU Press Center
French students sing in Chinese singing contest at NCKU
News Release
NCKU Press Center
Sculptures by international artists added to NCKU campus
NCKU Press Center
NCKU’s David robot shines at international competition
NCKU Press Center
Wall painting created by NCKU students to raise ecological awareness
NCKU Press Center
E-learning forum Asia kicks off at NCKU
NCKU Press Center
NCKU chair professor receives Y. Z. Hsu Scientific Award
NCKU Press Center
NCKU research team discovers new treatment for liver diseases
Banyan Forum
Opportunities
Activities
Editorial Group
NCKU research team discovers new treatment for liver diseases
NCKU Press Center
[Taipei, Taiwan, June 3, 2014]
A Tainan-based research team from National Cheng Kung University (NCKU) has discovered the pathogenesis of liver fibrosis and developed antibodies that reduce liver damage, inhibit hepatic fibrosis, and recover liver function.

Professor Ming-Shi Chang, PhD, Chair Professor of Biochemistry and Molecular Biology at NCKU, has led the team to make another breakthrough in their research on interleukin 20 (IL-20), the university revealed at a press conference on June 3.

Their research titled “IL-20 and IL-20R1 Antibodies Protect Against Liver Fibrosis” has been published in the May issue of Hepatology.

Currently, NCKU has been granted a patent in the United States of America, US 860347 B1, “Use of IL-20 Antagonists for Treating Liver Diseases”, which has attracted great interest from the biotechnology industry.

Hepatitis, fatty liver disease, and hepatotoxicity are some of the primary disorders that lead to the development of liver diseases, according to Professor Chang, who added that inflammation of the liver can evolve into liver fibrosis and cirrhosis, and that patients with liver cirrhosis at the final stage often develop liver cancer.

Inflammation is the source of many diseases, said Professor Chang. She also said that IL-20 is involved in several inflammatory diseases.


Copyright National Cheng Kung University